about
Improving management of patients with advanced cancerThe Analysis of the Relationship between Multiple Myeloma Cells and Their MicroenvironmentButein, a tetrahydroxychalcone, suppresses cancer-induced osteoclastogenesis through inhibition of receptor activator of nuclear factor-kappaB ligand signalingNew therapeutic agents for the treatment of bone diseases.Skeletal bone diseases impact the periodontium: a review of bisphosphonate therapy.Functional benefits are sustained after a program of supervised resistance exercise in cancer patients with bone metastases: longitudinal results of a pilot study.RANKL inhibition: Clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases
P2860
Q34413634-2ED6396D-5E12-4FD5-900A-350DB903E850Q34791709-D9CB90BB-F7BA-499D-AD16-83262C6A05F1Q35511177-419EE429-B875-49A2-8B41-25C1BB4CA2F1Q36161232-FB420071-3C15-4ED1-9FC4-BA92F6B36C81Q36723836-1F21AC7B-2816-4BF5-90A1-367127C04A77Q39272429-0526DBFE-9A5F-4992-B6C0-1ABAB6410E45Q57904702-6C9BE0AD-AEE0-4B75-A8EE-A78CCF431FCB
P2860
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Bisphosphonate therapy in the oncology setting.
@ast
Bisphosphonate therapy in the oncology setting.
@en
type
label
Bisphosphonate therapy in the oncology setting.
@ast
Bisphosphonate therapy in the oncology setting.
@en
prefLabel
Bisphosphonate therapy in the oncology setting.
@ast
Bisphosphonate therapy in the oncology setting.
@en
P2860
P356
P1476
Bisphosphonate therapy in the oncology setting.
@en
P2093
Allan Lipton
P2860
P304
P356
10.1517/14728214.8.2.469
P407
P577
2003-11-01T00:00:00Z